GENFIT S.A.(GNFT)

Description: GENFIT is a biopharmaceutical company focused on discovering and developing drug candidates and diagnostic solutions targeting liver diseases, in particular those of metabolic origin, and hepatobiliary diseases. GENFIT concentrates its R&D efforts in areas of high unmet medical needs corresponding to a lack of approved treatments. GENFIT’s lead proprietary compound, elafibranor, is a drug candidate currently being evaluated in one of the most advanced Phase 3 studies worldwide (RESOLVE-IT) in nonalcoholic steatohepatitis, or NASH, considered by regulatory authorities as a medical emergency because it is silent, with potentially severe consequences, and with a prevalence on the rise. Elafibranor has also obtained positive preliminary results in a Phase 2 clinical trial in primary biliary cholangitis, or PBC, a severe chronic liver disease. As part of its comprehensive approach to clinical management of NASH patients, GENFIT is conducting an ambitious discovery and development program aimed at providing patients and physicians with a blood-based test for the diagnosis of NASH, i.e. non-invasive and easy-to-access. With facilities in Lille and Paris, France, and Cambridge, MA (USA), the Company has approximately 150 employees.

---

Keywords: Medicine Biopharmaceutical Autoimmune Disease Alcohol Hepatitis Liver Disease Steatohepatitis Non Alcoholic Fatty Liver Disease Hepatology Diagnostic Solutions Liver Primary Biliary Cholangitis Obeticholic Acid Chronic Liver Disease Clinical Management Hepatobiliary Diseases

---

Home Page: www.genfit.com

GNFT Technical Analysis

Parc EurasantE
Loos, 59120
France
Phone: 33 3 20 16 40 00

---

Officers

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)